发明授权
![[1,7]naphthyridines as PDE4 inhibitors](/docs/US/2008-12-23/US07468370B2/abs.jpg.600x600.jpg)
- 专利标题： [1,7]naphthyridines as PDE4 inhibitors
- 专利标题（中）： [1,7]萘啶类作为PDE4抑制剂
-
申请号： US10538355申请日： 2003-12-15
-
公开(公告)号： US07468370B2公开(公告)日： 2008-12-23
- 发明人: Alastair Denholm , Thomas Hugo Keller , Clive McCarthy , Neil John Press , Roger John Taylor
- 申请人： Alastair Denholm , Thomas Hugo Keller , Clive McCarthy , Neil John Press , Roger John Taylor
- 申请人地址： CH Basel
- 专利权人： Novartis AG
- 当前专利权人： Novartis AG
- 当前专利权人地址： CH Basel
- 优先权： GB0229281.1 20021216
- 国际申请： PCT/EP03/14263 WO 20031215
- 国际公布： WO2004/055013 WO 20040701
- 主分类号： C07D471/02
- IPC分类号： C07D471/02 ; C07D401/00 ; A61K31/497 ; A61K31/44 ; A01N43/42
![[1,7]naphthyridines as PDE4 inhibitors](/abs-image/US/2008/12/23/US07468370B2/abs.jpg.150x150.jpg)
摘要：
Compounds of formula I in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by of phosphodiesterase type 4 or the down-regulation or inhibition of TNF-α release, particularly obstructive or inflammatory airways diseases. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
公开/授权文献
- US20060058338A1 [1,7]naphthyridines as pde4 inhibitors 公开/授权日：2006-03-16
信息查询
